LIXTE Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton cancer therapy company. Its primary asset is LB-100, a small molecule inhibitor of protein phosphatase 2A (PP2A) being tested in clinical trials for ovarian clear cell carcinoma, metastatic MSS colon cancer, and advanced soft tissue sarcoma. The company is also the majority shareholder of Liora Technologies Europe Ltd., which is developing the LiGHT System, an electronically controlled proton therapy system for treating tumors.
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001493152-26-014052 | EDGAR | 97K words |
| 2025-03-24 | 2024-12-31 | 0001641172-25-000208 | EDGAR | 99K words |
| 2024-03-19 | 2023-12-31 | 0001493152-24-010427 | EDGAR | 90K words |
| 2023-03-29 | 2022-12-31 | 0001493152-23-009386 | EDGAR | 90K words |
| 2022-03-21 | 2021-12-31 | 0001493152-22-007327 | EDGAR | — |
| 2021-03-26 | 2020-12-31 | 0001493152-21-006882 | EDGAR | — |
| 2020-03-25 | 2019-12-31 | 0001493152-20-004697 | EDGAR | — |
| 2019-03-25 | 2018-12-31 | 0001493152-19-003870 | EDGAR | — |
| 2018-03-23 | 2017-12-31 | 0001493152-18-003806 | EDGAR | — |
| 2017-03-29 | 2016-12-31 | 0001493152-17-002940 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001493152-26-038001 | EDGAR | 23K words |
| 2025-11-12 | 2025-09-30 | 0001493152-25-021941 | EDGAR | 50K words |
| 2025-08-07 | 2025-06-30 | 0001641172-25-022517 | EDGAR | 46K words |
| 2025-05-12 | 2025-03-31 | 0001641172-25-009575 | EDGAR | 40K words |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044810 | EDGAR | 42K words |
| 2024-08-08 | 2024-06-30 | 0001493152-24-030757 | EDGAR | 39K words |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018337 | EDGAR | 33K words |
| 2023-11-09 | 2023-09-30 | 0001493152-23-040115 | EDGAR | 38K words |
| 2023-08-09 | 2023-06-30 | 0001493152-23-027269 | EDGAR | 36K words |
| 2023-05-10 | 2023-03-31 | 0001493152-23-016069 | EDGAR | 31K words |
| 2022-11-08 | 2022-09-30 | 0001493152-22-030878 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001493152-22-021832 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-31 | 0001493152-26-035561 | EDGAR | 0K words |
| 2026-03-20 | 0001493152-26-011829 | EDGAR | 1K words |
| 2026-03-10 | 0001493152-26-009526 | EDGAR | 17K words |
| 2026-02-18 | 0001493152-26-007268 | EDGAR | 1K words |
| 2025-12-31 | 0001493152-25-029778 | EDGAR | 8K words |
| 2025-12-23 | 0001493152-25-028999 | EDGAR | 1K words |
| 2025-12-22 | 0001493152-25-028850 | EDGAR | 1K words |
| 2025-12-11 | 0001493152-25-027219 | EDGAR | 1K words |
| 2025-11-25 | 0001493152-25-024996 | EDGAR | 1K words |
| 2025-09-11 | 0001641172-25-027109 | EDGAR | 1K words |
242 total filings indexed. 210 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001335105 |
| Ticker | LIXT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.lixte.com |
| Listed | 2007-09-05 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LIXT (~200 tokens, structured JSON with cryptographic provenance)